Toxoplasma gondii Seroprevalence Among Blood Donors in Zahedan, Southeastern Iran

authors:

avatar Mohammad Jafari Modrek 1 , 2 , * , avatar Mohammad Mousavi 2 , avatar Ramin Saravani 3

Infectious Disease and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
Department of Parasitology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Department of Clinical Biochemistry, Cellular and Molecular Research Center, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran

how to cite: Jafari Modrek M, Mousavi M, Saravani R. Toxoplasma gondii Seroprevalence Among Blood Donors in Zahedan, Southeastern Iran. Int J Infect. 2014;1(2):e21111. https://doi.org/10.17795/iji-21111.

Abstract

Background:

Blood transfusion is one of the many ways, through which Toxoplasma Gondii (T. gondii), a protozoan parasite, can be transmitted to humans.

Objectives:

This cross sectional study aimed to evaluate the seroprevalence of toxoplasma infection and related epidemiological features among healthy blood donors.

Materials and Methods:

A total of 375 blood samples from donors were tested for specific T. gondii antibodies (IgG and IgM) by ELISA method, in Blood Transfusion Organization, Zahedan, Iran. Positive samples for T. gondii IgG were further tested for T. gondii IgM. A positive IgG test with a negative or positive IgM test was interpreted as a chronic or acute toxoplasmosis case, respectively.

Results:

From the total 375 blood donors, 94 samples (25%) were T. gondii IgG positive. No positive cases of anti-T. gondii IgM antibodies were found. The difference between age and presence of anti-Toxoplasma antibodies was statistically significant (P < 0.05). Other characteristics of blood donors, including male gender, ABO blood groups and having a history of blood transfusion showed no association with infection.

Conclusions:

Our results highlighted that 25% of blood donors were infected by Toxoplasma, prior to the sampling and it can relapse, when facing a decreased immunity level.

1. Background

Toxoplasmosis is one of the most widespread infections in animals and humans, caused by an intracellular obligatory parasite, Toxoplasma Gondii (T. gondii), which is usually transmitted to humans, orally (by ingesting food or water, contaminated with oocytes from infected cat feces or tissue cysts in meat). However, blood or leukocyte infusion, organ transplantation and transmission via the placenta are other possible routes of infection (1-3). The infection can result in severe consequences, including encephalitis, chorioretinitis and myocarditis in immunocompromised individuals, like transplant recipients and HIV-positive patients (4). It has been demonstrated that toxoplasma infection can be transmitted through blood transfusion (5). Since T. gondii organism may stay alive in citrated blood, at 5°C, for up to 50 days and the buffy coat (6), it is likely that toxoplasmosis could be acquired via blood or leukocyte transfusions, especially if parasitized leukocytes are transfused in a high concentration (6). Multiple blood units from different donors are regularly administered for children with thalassemia, sickle cell anemia and aplastic anemia who need regular, frequent and multiple transfusions for survival. Many studies have shown high prevalence of T. gondii antibodies in healthy volunteer blood donors (7-14), while pre-transfusion T. gondii screening has not been considered yet. Not a lot of studies have been conducted on the epidemiology of T. gondii infection in this region blood donors. Healthy seropositive blood donors, especially those who are in the acute phase of the infection, may have a major role in this scenario (15). The rate of toxoplasma infection in healthy blood donors, varies in different areas of the world and this mainly depends on the rate of infection in the community (10, 11, 13, 16-18). In some areas, like Northeast Brazil, north India and north Egypt, more than 50% of blood donors have been detected to be seropositive for toxoplasma infection (7, 16, 18). Lower rates of infection in blood donors have been reported from Taiwan (9.3%), Thailand (9.6%), Mexico (7.4%) and Turkey (19.5%) (9, 10, 13, 19). Lack of information about the status of toxoplasma infection in healthy blood donors in Southeastern Iran justified this study, to evaluate the seroprevalence of this infection and its relative epidemiological factors in asymptomatic healthy blood donors.

2. Objectives

The aim of this study was to determine the prevalence of T. gondii infection in blood donors in Zahedan city, Iran and to identify characteristics of blood donors associated with seropositivity.

3. Materials and Methods

3.1. Study Design

We performed a cross sectional study in the Blood Transfusion Organization (BTO) of Zahedan city, Iran. Samples were collected from voluntary blood donors and routinely tested for human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, HTLV1-HTLV 2, and Treponema pallidum.

3.2. Serological Tests

Serum samples were obtained from fresh whole blood, transferred from each blood service center of each county to the serology laboratory at the department of parasitology and mycology of Zahedan (Zahedan University of Medical Sciences, Zahedan, Iran) and kept at -20°C, until use. Serum samples were tested for anti-Toxoplasma IgG and IgM, using a commercial enzyme immunoassay kit (Pishtaz Teb Diagnostics, Tehran, Iran). Anti- T. gondii IgG antibodies levels > 14.5 UL/mL were considered positive. Anti-T. gondii IgM antibodies levels were assessed in samples that IgG anti-T. gondii were positive. Anti-T. gondii IgM antibodies levels > 1.1 UL/mL were considered positive. Samples with positive IgG and negative IgM anti-T. gondii antibodies were considered as chronic toxoplasmosis, while those with both positive IgG and IgM anti-T. gondii anti-bodies were considered as acute toxoplasmosis.

3.3. Analysis of Data

Results were analyzed using SPSS software (version 18), with a P Value < 0.05 taken as statistically significant. Chi-squared and Fisher exact tests were used to compare the seroprevalence values, related to the characteristics of the subjects.

4. Results

From the total of 375 blood donor samples, Anti T. gondii antibodies were detected in sera of 94 blood donors, corresponding to an overall seroprevalence of 25% in this population, all seropositive for IgG. Among IgG antibody positive samples, 83 were male (88.29%) and 11 were female (11.71%). The highest seroprevalence rate of Toxoplasma (38%) was found in the age group of 25-36, while the lowest seropositivity (20.7%) was seen in the age group of 17-25. The difference between age and presence of anti-Toxoplasma antibodies was statistically significant (P < 0.05). Blood group B was the most frequent group (29%) and blood group A was the least frequent (17%) blood group (Table 1). No correlation was found between Toxoplasma seropositivity and ABO or Rh blood group (P > 0.05). Moreover, no association was found between the occupation of participants and toxoplasma seropositivity (P > 0.05).

Table 1.

Demographic Characteristics of Blood Donors and Relative Seropositivity to T. gondii in Zahedan Province, Southern Iran

CharacteristicsFrequency No. (%)Donor With Anti-T. gondii IgG, No. (%)P Value
Gender> 0.05
Male333 (88.8)83 (24.92)
Female42 (11.2)11 (26.1)
Age group< 0.05
17-25232 (61.86)48 (20.7)
26-3593 (24.8)30 (32.25)
> 3650 (13.4)19 (38)
Blood group> 0.05
A99 (26.4)16 (17)
B112 (29.87)32 (29)
AB27 (7.2)7 (26)
O137 (36.53)37 (28)
Rh> 0.05
Positive285 (76)73 (25.6)
Negative90 (24)21 (23.4)

5. Discussion

Organism presence in blood, during the course of infection, ensures its transmission through transfusion (15). Moreover, the ability of organism to survive in the stored blood is another factor, increasing the chance of transmission through transfusion. It has been demonstrated that toxoplasma tachyzoites can survive in stored blood for several weeks (20). During the active infection course, toxoplasma might be present in blood and this would be a real threat for blood recipients, especially patients undergoing multiple transfusions or those requiring blood transfusion for transplantation management. The current study is the first seroprevalence study of toxoplasma infection among healthy blood donors in south of Iran. The Iranian Blood Transfusion Organization (IBTO) is a nationally qualified organization, performing blood transfusion procedures. This organization has a main center in each province and different branches in counties of each province. Recent data showed that there are 23 blood donors per 1000 populations in Iran. More than 90% of blood donations in Iran are from voluntary non-remunerated blood donors and the rest is donated as family replacement donation (21). In this study, 375 blood samples were assessed for IgG and IgM antibodies. Our results showed that the prevalence of anti-toxoplasma IgG was 25% and IgM antibodies were not found in any of the samples. It can be concluded that a chronic infection existed in blood donors, which had possibly occurred in a younger age (22). In comparison to previous studies conducted in Iran, our results were similar to those of Sharif et al. study (22%) (23). However the results were not similar to other studies in different parts of Iran. The prevalence was lower than reports from Salahi Moghaddam (68.4%), Assmar (51.8%) and Gorman (55.7%) (24-26) and higher than Gorbani's report (17.7%) (26). The result was also similar to other studies in other countries (4, 7, 8). In our study, the age group 25-36, had the highest toxoplasma infection rate and the prevalence rate increased by age. The reason might be due to the increased risk of exposure to infection sources with age. These results were in accordance with the results of Bahador Sarkari and other authors' study (27). In Caucasian populations, the carriers of AB blood group are the most susceptible group for T. gondii infection (28). In our study, the Iranian population studied, blood group B was associated with a higher T. gondii seroprevalence, compared to other blood groups. However, the difference was not statistically significant. This result is consistent with the results from Movayedi and Zamorano's study (29, 30). Consequently blood transfusion is considered another potential transmission route for toxoplasma infection, therefore, it is necessary to specify the major blood recipients. According to the official statistics, there are about 20000 patients with thalassemia in Iran, most of which live in Southeastern Iran). These patients with hematopoietic disorders need multiples transfusion courses. Therefore, we need a system to evaluate this infection in order to prevent infection transmission to this population (31). Since There is no a substitute for blood yet, transmission of any infection, including toxoplasmosis, concerns people. In a report, more than 50% of heart transplant recipients who were toxoplasma seronegative, became seropositive following the surgery, showed toxoplasmosis symptoms and finally died due to severe complications, like myocarditis (32).

Since T. gondii can be transmitted through blood transfusion, it may alarm patients with different kinds of immunodeficiency, who are at a higher risk of exposure to transfusion transmitted diseases. Therefore, appropriate strategies should be adapted to reduce the risk of acquiring toxoplasmosis through blood transfusion.

Acknowledgements

References

  • 1.

    Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, et al. Seroprevalence of Toxoplasma gondii in the Iranian general population: A systematic review and meta-analysis. Acta Trop. 2014. [PubMed ID: 24887263]. https://doi.org/10.1016/j.actatropica.2014.05.015.

  • 2.

    Gilbert R, Eskild P. up to date; 2013. Toxoplasmosis and pregnancy. Available from: http://www.uptodate.com/contents/ toxoplasmosis-and-pregnancy.

  • 3.

    Fallah M, Rabiee S, Matini M, Taherkhani H. Seroepidemiology of toxoplasmosis in primigravida women in Hamadan, Islamic Republic of Iran, 2004. East Mediterr Health J. 2008;14(1):163-71. [PubMed ID: 18557464].

  • 4.

    Nissapatorn V. Toxoplasmosis in HIV/AIDS: a living legacy. Southeast Asian J Trop Med Public Health. 2009;40(6):1158-78. [PubMed ID: 20578449].

  • 5.

    Singh G, Sehgal R. Transfusion-transmitted parasitic infections. Asian J Transfus Sci. 2010;4(2):73-7. [PubMed ID: 20859503]. https://doi.org/10.4103/0973-6247.67018.

  • 6.

    Siegel SE, Lunde MN, Gelderman AH, Halterman RH, Brown JA, Levine AS, et al. Transmission of toxoplasmosis by leukocyte transfusion. Blood. 1971;37(4):388-94. [PubMed ID: 4927414].

  • 7.

    Sundar P, Mahadevan A, Jayshree RS, Subbakrishna DK, Shankar SK. Toxoplasma seroprevalence in healthy voluntary blood donors from urban Karnataka. Indian J Med Res. 2007;126(1):50-5. [PubMed ID: 17890824].

  • 8.

    Nissapatorn V, Noor Azmi MA, Cho SM, Fong MY, Init I, Rohela M, et al. Toxoplasmosis: prevalence and risk factors. J Obstet Gynaecol. 2003;23(6):618-24. [PubMed ID: 14617462]. https://doi.org/10.1080/01443610310001604376.

  • 9.

    Alvarado-Esquivel C, Mercado-Suarez MF, Rodriguez-Briones A, Fallad-Torres L, Ayala-Ayala JO, Nevarez-Piedra LJ, et al. Seroepidemiology of infection with Toxoplasma gondii in healthy blood donors of Durango, Mexico. BMC Infect Dis. 2007;7:75. [PubMed ID: 17629901]. https://doi.org/10.1186/1471-2334-7-75.

  • 10.

    Chiang TY, Hsieh HH, Kuo MC, Chiu KT, Lin WC, Fan CK, et al. Seroepidemiology of Toxoplasma gondii Infection among healthy blood donors in Taiwan. PLoS One. 2012;7(10). ee48139. [PubMed ID: 23133557]. https://doi.org/10.1371/journal.pone.0048139.

  • 11.

    Elhence P, Agarwal P, Prasad KN, Chaudhary RK. Seroprevalence of Toxoplasma gondii antibodies in North Indian blood donors: implications for transfusion transmissible toxoplasmosis. Transfus Apher Sci. 2010;43(1):37-40. [PubMed ID: 20605111]. https://doi.org/10.1016/j.transci.2010.05.004.

  • 12.

    Liu Y, Zheng K, Chen M, Fu L, Du W, Shi Z. Study on detecting antibodies to Toxoplasma gondii in pooled serum of blood donors by Dot-IGSS. Southeast Asian J Trop Med Public Health. 2001;32(3):558-61. [PubMed ID: 11944717].

  • 13.

    Yazar S, Eser B, Yay M. Prevalence of anti-toxoplasma Gondii antibodies in Turkish blood donors. Ethiop Med J. 2006;44(3):257-61. [PubMed ID: 17447392].

  • 14.

    Yilmaz GR, Babur C, Kilic S, Taylan Ozkan A, Beyaz E, Karakoc AE. [Short communication: investigation of Toxoplasma gondii antibodies in blood donors by Sabin-Feldman Dye Test]. Mikrobiyol Bul. 2006;40(4):375-81. [PubMed ID: 17205696].

  • 15.

    Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10):2080-99. [PubMed ID: 20738828]. https://doi.org/10.1111/j.1537-2995.2010.02851.x.

  • 16.

    Coelho RA, Kobayashi M, Carvalho LB, Jr. Prevalence of IgG antibodies specific to Toxoplasma gondii among blood donors in Recife, Northeast Brazil. Rev Inst Med Trop Sao Paulo. 2003;45(4):229-31. [PubMed ID: 14502353].

  • 17.

    Makki SM, Abdel-Tawab AH. Anti-Toxoplasma gondii antibodies among volunteer blood donors in eastern Saudi Arabia. J Egypt Soc Parasitol. 2010;40(2):401-12. [PubMed ID: 21246947].

  • 18.

    Elsheikha HM, Azab MS, Abousamra NK, Rahbar MH, Elghannam DM, Raafat D. Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt. Parasitol Res. 2009;104(6):1471-6. [PubMed ID: 19198880]. https://doi.org/10.1007/s00436-009-1350-z.

  • 19.

    Pinlaor S, Ieamviteevanich K, Pinlaor P, Maleewong W, Pipitgool V. Seroprevalence of specific total immunoglobulin (Ig), IgG and IgM antibodies to Toxoplasma gondii in blood donors from Loei Province, Northeast Thailand. Southeast Asian J Trop Med Public Health. 2000;31(1):123-7. [PubMed ID: 11023078].

  • 20.

    Martin AM, Liu T, Lynn BC, Sinai AP. The Toxoplasma gondii parasitophorous vacuole membrane: transactions across the border. J Eukaryot Microbiol. 2007;54(1):25-8. [PubMed ID: 17300514]. https://doi.org/10.1111/j.1550-7408.2006.00230.x.

  • 21.

    Gharehbaghian A, Abolghasemi H, Namini MT. Status of blood transfusion services in Iran. Asian J Transfus Sci. 2008;2(1):13-7. [PubMed ID: 20041072]. https://doi.org/10.4103/0973-6247.39505.

  • 22.

    Shaddel M, Mirzaii-Dizgah I, Hoshangi M. Anti-Toxoplasma gondii Antibody Levels in Blood Supply of Shiraz Blood Transfusion Institute, Iran. Iranian J Parasitol. 2014;9(1):120-4.

  • 23.

    Sharif M, Daryani A, Barzegar G, Nasrolahei M. A seroepidemiological survey for toxoplasmosis among schoolchildren of Sari, Northern Iran. Trop Biomed. 2010;27(2):220-5. [PubMed ID: 20962719].

  • 24.

    Salahi-Moghaddam A, Hafizi A. A serological study on Toxoplasma gondii infection among people in south of Tehran, Iran. Korean J Parasitol. 2009;47(1):61-3. [PubMed ID: 19290094]. https://doi.org/10.3347/kjp.2009.47.1.61.

  • 25.

    Assmar M, Amirkhani A, Piazak N, Hovanesian A, Kooloobandi A, Etessami R. [Toxoplasmosis in Iran. Results of a seroepidemiological study]. Bull Soc Pathol Exot. 1997;90(1):19-21. [PubMed ID: 9264742].

  • 26.

    Ghorbani M, Edrissian GH, Assad N. Serological survey of toxoplasmosis in the northern part of Iran, using indirect fluorescent antibody technique. Trans R Soc Trop Med Hyg. 1978;72(4):369-71. [PubMed ID: 360498].

  • 27.

    Sarkari B, Shafiei R, Zare M, Sohrabpour S, Kasraian L. Seroprevalence and molecular diagnosis of Toxoplasma gondii infection among blood donors in southern Iran. J Infect Dev Ctries. 2014;8(4):543-7. [PubMed ID: 24727522]. https://doi.org/10.3855/jidc.3831.

  • 28.

    Kolbekova P, Kourbatova E, Novotna M, Kodym P, Flegr J. New and old risk-factors forToxoplasma gondiiinfection: prospective cross-sectional study among military personnel in the Czech Republic. Clinical Microbiology and Infection. 2007;13(10):1012-7. https://doi.org/10.1111/j.1469-0691.2007.01771.x.

  • 29.

    Zamorano CG, Contreras MC, Villalobos S, Sandoval L, Salinas P. [Seroepidemiological survey of human toxoplasmosis in Osorno, Region X, Chile, 1998]. Bol Chil Parasitol. 1999;54(1-2):33-6. [PubMed ID: 10488589].

  • 30.

    Movayedi B. The prevalence of infection with the protozoan blood transfusion of the blood donor base. J Med Sci Isfahan. 2000;4(4):217-31.

  • 31.

    Hossain A. Investigate the reasons for deferral of donors attending the Blood Transfusion Center, Tehran. Hakim Res J. 2002;5(2):121.

  • 32.

    Strabelli TM, Siciliano RF, Vidal Campos S, Bianchi Castelli J, Bacal F, Bocchi EA, et al. Toxoplasma gondii Myocarditis after Adult Heart Transplantation: Successful Prophylaxis with Pyrimethamine. J Trop Med. 2012;2012:853562. [PubMed ID: 23209479]. https://doi.org/10.1155/2012/853562.